Fluoxetine in Progressive Multiple Sclerosis (FLUOX-PMS) : study protocol for a randomized controlled trial

Background: Currently available disease-modifying treatments acting by modifying the immune response are ineffective in progressive multiple sclerosis (MS), which is caused by a widespread axonal degeneration. Mechanisms suspected to be involved in this widespread axonal degeneration are reduced axonal energy metabolism, axonal glutamate toxicity, and reduced cerebral blood flow. Fluoxetine might theoretically reduce axonal degeneration in MS because it stimulates energy metabolism through enhancing glycogenolysis, stimulates the production of brain-derived neurotrophic factor, and dilates cerebral arterioles. The current document presents the protocol of a clinical trial to test the hypothesis that fluoxetine slows down the progressive phase of MS. Methods/Design: The FLUOX-PMS trial is a multi-center, randomized, controlled and double-blind clinical study. A total of 120 patients with the diagnosis of either secondary or primary progressive MS will be treated either by fluoxetine (40 mg daily) or placebo for a total period of 108 weeks. The primary endpoint is the time to confirmed disease progression defined as either at least a 20% increase in the timed 25-Foot Walk or at least a 20% increase in the 9-Hole Peg Test. Secondary endpoints include the Hauser ambulation index, cognitive changes, fatigue, magnetic resonance imaging of the brain, and in a small subgroup optical coherence tomography. Discussion: The FLUOX-PMS trial will gives us information as to whether fluoxetine has neuroprotective effects in patients with progressive MS

Spatial compatibility with a two-dimensional stimulus arrangement

In this study, spatial compatibility of two-dimensional stimulus arrays versus one-dimensional response and effector arrays was investigated. A two-choice reaction time task was performed with rotating stimuli arranged on the periphery of a black vertical disk. Response was bimanual, with a crossed- and uncrossed hands condition. Depending on the cues presented, subjects tended to use different relations in responding. Furthermore, it was demonstrated that a second dimension in the stimulus arrangement could improve performance in some situations, especially if the transposition of dimensions was facilitated by spatial cues. © 1984, Psychonomic Society, Inc. All rights reserved.SCOPUS: ar.jinfo:eu-repo/semantics/publishe

Châteaux merveilleux en Belgique.

KU

Up-scalable sheet-to-sheet production of high efficiency perovskite module and solar cells on 6-in. substrate using slot die coating

Scalable sheet-to-sheet slot die coating processes have been demonstrated for perovskite solar cells and modules. The processes have been developed on 6 in. × 6 in. glass/ITO substrates for two functional layers: the perovskite photo-active layer and the Spiro-OMeTAD hole transport layer. Perovskite solar cells produced using these slot die coating processes demonstrate device performances identical to the spin coated devices. All manufactured devices illustrate a high level of reproducibility. The developed slot die coating processes were also used for the manufacturing of perovskite PV modules. Large area modules of 12.5 × 13.5 cm2 were realized by slot die coating on 6 in. × 6 in. substrates in combination with newly developed laser ablation processes for conventional P1-P2-P3 monolithic cell interconnections. The modules demonstrate power conversion efficiencies above 10%, with a power output of 1.7 W. This achievement is an important milestone in the development of up-scalable manufacturing technologies for perovskite PV modules

Up-scalable sheet-to-sheet production of high efficiency perovskite module and solar cells on 6-in. substrate using slot die coating

\u3cp\u3eScalable sheet-to-sheet slot die coating processes have been demonstrated for perovskite solar cells and modules. The processes have been developed on 6 in. × 6 in. glass/ITO substrates for two functional layers: the perovskite photo-active layer and the Spiro-OMeTAD hole transport layer. Perovskite solar cells produced using these slot die coating processes demonstrate device performances identical to the spin coated devices. All manufactured devices illustrate a high level of reproducibility. The developed slot die coating processes were also used for the manufacturing of perovskite PV modules. Large area modules of 12.5 × 13.5 cm\u3csup\u3e2\u3c/sup\u3e were realized by slot die coating on 6 in. × 6 in. substrates in combination with newly developed laser ablation processes for conventional P1-P2-P3 monolithic cell interconnections. The modules demonstrate power conversion efficiencies above 10%, with a power output of 1.7 W. This achievement is an important milestone in the development of up-scalable manufacturing technologies for perovskite PV modules.\u3c/p\u3

Fluoxetine in progressive multiple sclerosis : the FLUOX-PMS trial

Background: Preclinical studies suggest that fluoxetine has neuroprotective properties that might reduce axonal degeneration in multiple sclerosis (MS). Objective: To determine whether fluoxetine slows accumulation of disability in progressive MS. Methods: In a double-blind multicenter phase 2 trial, patients with primary or secondary progressive MS were randomized to fluoxetine 40 mg/day or placebo for a period of 108 weeks. Clinical assessments were performed every 12 weeks by trained study nurses who visited the patients at their home. The primary outcome was the time to a 12-week confirmed 20% increase in the Timed 25 Foot Walk or 9-Hole Peg test. Secondary outcomes included the Hauser ambulation index, cognitive tests, fatigue, and brain magnetic resonance imaging (MRI). Results: In the efficacy analysis, 69 patients received fluoxetine and 68 patients received placebo. Using the log-rank test (p = 0.258) and Cox regression analysis (p = 0.253), we found no significant difference in the primary outcome between the two groups. Due to an unexpected slow rate of progression in the placebo group, there was insufficient statistical power to detect a potential benefit of fluoxetine. We found no differences between the two groups for secondary outcomes. Conclusion: The trial failed to demonstrate a neuroprotective effect of fluoxetine in patients with progressive MS

Fluoxetine in progressive multiple sclerosis: The FLUOX-PMS trial

BACKGROUND: Preclinical studies suggest that fluoxetine has neuroprotective properties that might reduce axonal degeneration in multiple sclerosis (MS). OBJECTIVE: To determine whether fluoxetine slows accumulation of disability in progressive MS. METHODS: In a double-blind multicenter phase 2 trial, patients with primary or secondary progressive MS were randomized to fluoxetine 40 mg/day or placebo for a period of 108 weeks. Clinical assessments were performed every 12 weeks by trained study nurses who visited the patients at their home. The primary outcome was the time to a 12-week confirmed 20% increase in the Timed 25 Foot Walk or 9-Hole Peg test. Secondary outcomes included the Hauser ambulation index, cognitive tests, fatigue, and brain magnetic resonance imaging (MRI). RESULTS: In the efficacy analysis, 69 patients received fluoxetine and 68 patients received placebo. Using the log-rank test (p = 0.258) and Cox regression analysis (p = 0.253), we found no significant difference in the primary outcome between the two groups. Due to an unexpected slow rate of progression in the placebo group, there was insufficient statistical power to detect a potential benefit of fluoxetine. We found no differences between the two groups for secondary outcomes. CONCLUSION: The trial failed to demonstrate a neuroprotective effect of fluoxetine in patients with progressive MS.status: publishe

Impact on disease mortality of clinical, biological, and virological characteristics at hospital admission and overtime in COVID‐19 patients

International audienc

Long-term neurological symptoms after acute COVID-19 illness requiring hospitalization in adult patients: insights from the ISARIC-COVID-19 follow-up study

in this study we aimed to characterize the type and prevalence of neurological symptoms related to neurological long-COVID-19 from a large international multicenter cohort of adults after discharge from hospital for acute COVID-19